Suppr超能文献

长效钙通道阻滞剂在血液透析日的降压作用——苯磺酸氨氯地平和硝苯地平控释片的随机交叉试验

Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days--a randomized crossover trial between benidipine and nifedipine CR.

作者信息

Kojima Masayoshi, Taniguchi Masahito, Sato Koichi, Ueda Ryuzo, Dohi Yasuaki

机构信息

Department of Internal Medicine, Komono Kosei Hospital, Komono, Japan.

出版信息

Nephron Clin Pract. 2004;97(2):c49-53. doi: 10.1159/000078400.

Abstract

BACKGROUND/AIMS: Since antihypertensive effects of most calcium channel blockers largely depend on their plasma concentrations, a rapid increase in blood pressure may occur as circulating levels of such blockers decrease after hemodialysis. Thus, the effects of benidipine and nifedipine CR (extended-release coated tablets, Adalat CR), which are long-acting calcium channel blockers, on post-hemodialytic blood pressures were investigated.

METHODS

A randomized crossover trial was carried out with 10 hypertensive patients on chronic maintenance hemodialysis. Patients were assigned to receive benidipine (4-8 mg/day) or nifedipine CR (20-40 mg/day), and after 4 weeks, 24-hour ambulatory blood pressure monitoring was performed on the day of hemodialysis and blood samples were obtained before and after hemodialysis to measure plasma concentrations of the blockers. The calcium channel blockers were then exchanged in each patient and the same protocol was repeated.

RESULTS

The pattern of fluctuation of blood pressure differed markedly between the treatment with benidipine and nifedipine CR. Under treatment with nifedipine CR, rapid increase in blood pressure was observed after hemodialysis, while blood pressure remained at favorable levels with benidipine. Plasma concentrations of the blockers were significantly decreased by hemodialysis.

CONCLUSION

Benidipine exerts more sustained antihypertensive effects than expected from its disposition in plasma. The stable depressor effects of benidipine even after hemodialysis may contribute to favorable control of blood pressure in this population.

摘要

背景/目的:由于大多数钙通道阻滞剂的降压作用很大程度上取决于其血浆浓度,因此在血液透析后,随着此类阻滞剂循环水平的降低,血压可能会迅速升高。因此,研究了长效钙通道阻滞剂贝尼地平与硝苯地平控释片(Adalat CR)对血液透析后血压的影响。

方法

对10例接受慢性维持性血液透析的高血压患者进行了一项随机交叉试验。患者被分配接受贝尼地平(4 - 8毫克/天)或硝苯地平控释片(20 - 40毫克/天),4周后,在血液透析当天进行24小时动态血压监测,并在血液透析前后采集血样以测量阻滞剂的血浆浓度。然后在每位患者中更换钙通道阻滞剂,并重复相同的方案。

结果

贝尼地平和硝苯地平控释片治疗期间血压波动模式明显不同。在硝苯地平控释片治疗下,血液透析后观察到血压迅速升高,而使用贝尼地平时血压保持在良好水平。血液透析使阻滞剂的血浆浓度显著降低。

结论

贝尼地平发挥的降压作用比根据其在血浆中的分布预期的更为持久。即使在血液透析后,贝尼地平稳定的降压作用可能有助于该人群血压的良好控制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验